The DOI matches its Crossref record; 135 of the 136 references it cites were found in a registry or an index.
Self-amplifying RNA vaccines for infectious diseases
Open accessAbstract
Vaccinology is shifting toward synthetic RNA platforms which allow for rapid, scalable, and cell-free manufacturing of prophylactic and therapeutic vaccines. The simple development pipeline is based on in vitro transcription of antigen-encoding sequences or immunotherapies as synthetic RNA transcripts, which are then formulated for delivery. This approach may enable a quicker response to emerging disease outbreaks, as is evident from the swift pursuit of RNA vaccine candidates for the global SARS-CoV-2 pandemic. Both conventional and self-amplifying RNAs have shown protective immunization in preclinical studies against multiple infectious diseases including influenza, RSV, Rabies, Ebola, and HIV-1. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared to conventional mRNA, suggesting this technology may improve immunization. This review will explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages of synthetic manufacturing approaches, and their potential for preventing and treating chronic infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“saRNAs use an RNA-dependent RNA polymerase from an alphavirus and the corresponding conserved sequence elements at the 5′ and 3′ ends for replication, leading to robust and durable expression of encoded protein cargo5–7.”
From Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredIn the citing paper
“Similar to other mRNA vaccine platforms, saRNA facilitates rapid candidate design and development, as well as cell-free molecule synthesis.152”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [152]
In the citing paper
“The virus-derived polymerase amplifies mRNA transcripts intracellularly, enabling the expression of large amounts of antigen with reduced mRNA doses9.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla‐Pazner, S., Tomaras, G. D., Alam, S. M., Evans, D. T., Montefiori, D. C., Karnasuta, C., Sutthent, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113425 · Cited by 1,810
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,478
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
DNA vaccines: ready for prime time?
Kutzler, M. A., & Weiner, D. B. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2432 · Cited by 1,077
Reversible methylation of m6Am in the 5′ cap controls mRNA stability
Mauer, J., Luo, X., Blanjoie, A., Jiao, X., Grozhik, A. V., Patil, D. P., Linder, B., Pickering, B. F., Vasseur, J., Chen, Q., et al. (2016) · Nature · doi:10.1038/nature21022 · Cited by 1,072
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066
2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members
Daffis, S., Szretter, K. J., Schriewer, J. M., Li, J., Youn, S., Errett, J. S., Lin, T., Schneller, S. W., Züst, R., Dong, H., et al. (2010) · Nature · doi:10.1038/nature09489 · Cited by 910
Research works printed but not linked: 1
- Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003;77:10394–403. · DOI · Paper page
Cited by
Sorted by citations
Items 401–488 of 488
Lim, T. K. Y., Ritoux, A., Paine, L. W., Ferguson, L., Abdul, T., Grundy, L. J., & Smith, E. S. J. (2025) · eLife · doi:10.7554/elife.105978.2 · Cited by 1
Polymer-lipid hybrid nanoparticle enhances mRNA delivery and T cell-mediated immunityPreprint
Cai, X., Chen, M., Cao, G., Asby, N. W., Elli, D., Gula, H., Nicolaescu, V. I., Nguyen, D.-T., Huang, X., Dangi, T., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.22.701138 · Cited by 1
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9109248/v1 · Cited by 1
Liebisch-Rey, H., Bustos, J. F., Salazar-Reggeti, R., Pérez, J. A. V., Isaza, E. R., Vargas, M. A. C., Silva-Amaro, A. C., González, V. I. M., Moreno, L. B., Abreu, D. A. R. D., et al. (2021) · Salud Uninorte · doi:10.14482/sun.37.1.616.241
Chupin, C., Pizzorno, A., Traversier, A., Brun, P., Ogonczyk-Makowska, D., Padey, B., Milesi, C., Dulière, V., Laurent, E., Julien, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458186
Rice, A., Verma, M., Voigt, E. A., Battisti, P., Beaver, S., Reed, S., Dinkins, K., Mody, S., Zakin, L., Tanaka, S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.29.470440
Vera-Peralta, H., Vigne, C., & Mura, M. (2022) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(22)00097-1
A stochastic model for hepatitis C viral infection dynamics with the innate immune response
Castaño-Arcila, M., & Rodríguez-González, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-32-390171-0.00018-4
Potential Autoimmunity of SARS CoV-2 Nucleic Acid-based Vaccination: What Should We Know?Preprint
Kelleni, M. T. (2021) · doi:10.31219/osf.io/3k4bd
mRNA based vaccines as an alternative to conventional vaccine approaches
Zubda-tul, H., & Muhammad, Q. (2022) · Open Journal of Environmental Biology · doi:10.17352/ojeb.000026
RNA-based vaccines – types, strategies of delivery and overview of RNA vaccines
Rusinowska, B., Tybulczuk, B., Satora, M., Kozioł, M., & Sikora, K. O. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.07.090
Jackson, N. A. C. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_2
Madadha, M. E. A., Rayyan, R., Ahmed, K., Al-Sanouri, N., Demour, S. A., & Ahmad, M. M. (2022) · Cogent Public Health · doi:10.1080/27707571.2022.2145756
Messenger RNA Nanovaccine in Cancer Immunotherapy
Li, M., & Zhang, H. (2022) · Springer eBooks · doi:10.1007/978-3-031-17831-3_9
Appraisal of Some of the Key Postulates Underlying mRNA Vaccines
Mueller, S. (2022) · Springer eBooks · doi:10.1007/978-3-031-18903-6_2
Polymerase Chain Reaction: Applications in Gene and Cell Therapy Studies
Murphy, J., Herr, K., & Vepachedu, V. R. (2023) · Biochemistry · doi:10.5772/intechopen.110837
General Workflow for Studying Performance of RNA-Based Lipid NanoparticlesPreprint
Ma, Y., Li, S., Lin, X., & Chen, Y. (2023) · doi:10.22541/au.170054109.90988897/v1
Mahardika, G. N., Pharmawati, M., & Ramona, Y. (2023) · jurnal veteriner · doi:10.19087/jveteriner.2023.24.2.201
Delivery of Rna Drugs: Beyond the Liver, More than VaccinePreprint
Elnaggar, M. G., He, Y., & Yeo, Y. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4657914
How much genuine is mRNA vaccine: Transferring message of small size grabbed Nobel Prize
Goswami, T. K. (2023) · Indian Journal of Animal Health · doi:10.36062/ijah.2023.15223
Vilpreux, C., Martinez, G., Court, M., Appaix, F., Duteyrat, J.-L., Henry, M., Vollaire, J., Ayad, C., Yavz, A., Macedo, L. D., et al. (2024) · eLife · doi:10.7554/elife.94514.1
Vilpreux, C., Fourquin, P., Martinez, G., Court, M., Appaix, F., Duteyrat, J.-L., Henry, M., Vollaire, J., Ayad, C., Yavuz, A., et al. (2024) · eLife · doi:10.7554/elife.94514
As vacinas para COVID-19 e suas tecnologias: potencial e perspectivas
Nunes, V. A., Chambergo, F. S., Akamatsu, M. A., & Ho, P. L. (2022) · Cadernos de História da Ciência · doi:10.47692/cadhistcienc.2021.v15.36516
Design of Novel Synthetic RNA Replicons Based on Emesvirus zinderi
Wagner, A., & Mutschler, H. (2024) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00097
Self-Replicating RNA Derived from the Genomes of Positive-Strand RNA Viruses
Meyers, G., & Tews, B. A. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3770-8_2
Lloren, K. K. S., Sivasankar, C., & Lee, J. H. (2024) · Veterinary Microbiology · doi:10.1016/j.vetmic.2024.110151
McCarthy, F. (2024) · Queensland University of Technology · doi:10.5204/thesis.eprints.251561
Further therapeutic applications of mRNA and saRNA
Hillery, A. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-28934-7.00007-8 · Cited by 1
Lee, J. H., Park, J.-Y., & Senevirathne, A. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4946394
Unveiling Fundamentals and Research Opportunities of mRNA Technology
Kumar, D., Singh, A., Kaviraj, S., & Singh, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-0896-3_5
COVID-19 Vaccine Manufacturing Processes: Making the Molecules to Solve the Pandemic
Romine, J. A. S., Kolodziej, S. A., Vetter, T., & Dux, M. P. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_8
Mechanism of Vaccine Development
Thorat, N. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-86185-7_4
Lim, T. K. Y., Ritoux, A., Paine, L. W., Ferguson, L., Abdul, T., & Smith, E. S. J. (2025) · eLife · doi:10.7554/elife.105978.1
Historical Overview of RNA Therapeutics
Saw, P. E., & Song, E. (2025) · Springer eBooks · doi:10.1007/978-981-96-3041-7_1
Self-amplifying mRNA expression is governed by mitochondrial machinery and ACSL4Preprint
Tshering, L. F., Wang, C., Xiang, Q., Kundu, S., Solórzano, A., Chaparro‐Riggers, J. F., Lin, L., & Paksa, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.13.659366
Comparative Analysis of Two Vector Systems in mRNA Vaccine Development
Ohanube, G. A. K., & Obeta, U. M. (2021) · Interdisciplinary Research in Medical Sciences Specialty · doi:10.51847/xcjuchjjzh
Reverse and Structural Viral and Bacterial Vaccine Design
Ponnusamy, N., Ravi, N., Palanisamy, T. B., Ahmad, F., & Arumugam, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-77911-4_7
Biernat, A. K., Floriańczyk, A., Romanowicz, E., Kołdyj, A., Ozdarska, A., Lampart, M., Rupińska, A., Krzewska, K., & Skarakhodava, H. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3510
Investigation of in vitro delivery conditions for self-amplifying mRNA
Li, W., Wang, Y., Huo, Y., & Lu, Y. (2025) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-025-03215-4
Advances of mRNA vaccines in genitourinary cancers
Shen, Y.-M., Wan, F., Xu, H., Yu, L., Huang, S., Ye, D., & Dai, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189427
Levine, K. S., Blanc, R., Wang, Q., Malca, H., Sekulovich, R. E., Jin, H., Liu, S. N., Verhoeven, C., Sullivan, B. M., Smolenov, I. V., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.1295
Safarchi, A., Fatima, S., Ayati, Z., & Vafaee, F. (2021) · Figshare · doi:10.6084/m9.figshare.16388173
Guan, X., Cho, H., Qian, S., Liu, Q., & Du, L. (2026) · Vaccines · doi:10.3390/vaccines14010078 · Cited by 1
Vilpreux, C., Fourquin, P., Martinez, G., Court, M., Appaix, F., Duteyrat, J.-L., Henry, M., Vollaire, J., Ayad, C., Yavuz, A., et al. (2026) · eLife · doi:10.7554/elife.94514.3
Gupta, J., & Kumar, R. (2026) · Current Research in Translational Medicine · doi:10.1016/j.retram.2026.103577
Human immunodeficiency virus vaccines: Advances, challenges and future perspectives
Varatharajan, S., Krishnasai, S., & Girish, C. (2026) · World Journal of Virology · doi:10.5501/wjv.v15.i1.116055
LNP-mRNA immunogenicity and toxicity
Thalla, M., Pasika, S. R., Bulusu, R., Reddy, D. S., Mundrathi, V., & Shukla, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00008-2
An RNA-to-RNA pipeline for rapid antiviral antibody development
Hodge, E. A., Archer, J. F., Anderson, J. S., Warner, N. L., Tremblay, J., Klose, T., Park, S., Hinkley, T. C., Khandhar, A. P., Kuhn, R., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.04.021
Biological Therapies: A New Frontier in Health Care
Abdel-Wahhab, M. A., Akl, E. M., El‐Nekeety, A. A., & Mehaya, F. M. (2026) · Springer eBooks · doi:10.1007/978-981-95-6378-4_4
Albarghash, R., Jacobsen, C., & Kefalakes, H. (2026) · Antiviral Research · doi:10.1016/j.antiviral.2026.106416
Synthetic nucleic acids in a post-agent biosecurity Era
Hofman-Bang, J., Nielsen, K. F., Petersson, S. J., & Martel, C. J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1819026
Thomas, A., Ho, T. K. C., Chishimba, S., Kurtovic, L., D'souza, C. S., & Beeson, J. G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.29.721807
Strategies of HIV-1 Vaccines Based on mRNA Platforms
Liu, P. C., Zhong-Yue, F. A. N. G., Chen, X., Shao-Wei, L. I., & Ying, G. U. (2026) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/j.pibb.2025.0511
Non-coding RNAs: Therapeutic Implications in Cancers
Alves, R., Jorge, J., Costa, M. I., Lapa, B., Sarmento‐Ribeiro, A. B., & Gonçalves, A. C. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_10
Closing the loop: An RNA-to-RNA pipeline for on-demand antiviral antibodies
Wang, S., Miao, X., & Wei, W. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.004
Transforming cancer treatment through immunotherapy innovations
Mukherjee, S., Pramanick, A., & Bariar, V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44181-3.00013-8
A receptor-Fc based SFV replicon Trim-Away platform for targeted viral protein degradation
Han, Y., Dong, Q., Tian, Z., Wang, X. G., Wang, P., Liu, Q., Liu, Y., Guo, Q., & Zhang, S. (2026) · Virology Journal · doi:10.1186/s12985-026-03235-w
Applications of Recombinant DNA Technology in Medicine: A Comprehensive Review
Kumar, K. (2026) · Molecular Biotechnology · doi:10.1007/s12033-026-01595-w
Maeda, H., Igarashi, A., Mitsui, S., Suzuki, K., Kutomi, T., Fujino, H., Onoe, T., Kimura, T., Ichigi, Y., Kozai, H., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128964
Kim, B. K., Park, J.-H., Choi, W.-S., Oh, S., An, S. H., Lee, G. C., Chokkakula, S., Kim, C.-U., Jeong, J. H., Min, S. C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.047
Nanotechnology-Mediated Delivery of Vaccines in COVID-19 Management
Nakka, N. M. R., Rachamala, H. K., Nakka, S. B., Chakraborty, A., & Angom, R. S. (2026) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-032-29006-9_14
Gottipamula, S., & Krishnan, V. N. (2026) · Biotechnology and Bioengineering · doi:10.1002/bit.70324
Lipid nanoparticle-based multi-scale systemic immune programming for cancer therapy
Lin, X., Li, Y., Shen, X., Li, B., & Xu, Y. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.007
Zhang, B., Cai, Y., Deng, C., Huang, X., Yao, C., Li, X., Gao, L., Wu, Y., Chen, J., Jiang, J., et al. (2026) · Microsystems & Nanoengineering · doi:10.1038/s41378-026-01359-1
Advances in immunotherapy for HPV-associated malignancies: emerging strategies and clinical progress
Alsalloum, A., Zakhareva, A. P., Lopatnikova, J., & Sennikov, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1897025
Wen, Z., Long, Y., Shi, W., Song, W., Xu, R., Zhan, X., Wang, X., Su, R., Wang, Y., & Fei, J. (2026) · iScience · doi:10.1016/j.isci.2026.117519
Vaccines, Disinformation, & the Legacy of Maurice Hilleman
Silva, H. M. (2026) · The American Biology Teacher · doi:10.1525/abt.2026.88.7.377
Dewar, E. A., Swartz, A. R., Tuberty, K., & Gouveia, A. (2026) · Vaccines · doi:10.3390/vaccines14100865
Inam, M., Jamshed, M., & Osman, A. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2737475
Navigating the Transition to RNA-Based Influenza Vaccines: A State-of-the-Art Review
Panagiotopoulos, A.-P., Tsakri, D., Laskaris, A., Saldari, C., Ranellou, K., Mariolis, I., Tsakris, A., & Anastassopoulou, C. G. (2026) · Vaccines · doi:10.3390/vaccines14100874
The expression window as a safety parameter for mRNA medicines
Tani, H. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118513
Development of mRNA vaccines against herpes zoster
Li, D., Luo, J., Wang, J., Wang, L., Zhang, M., Shen, J., Chu, X., Mao, W., Zhang, Y., & Xin, H. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2746289
Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development
Ma, X., Zhao, M., Xu, Y., Jiang, Y., Yang, Y., Lei, L., & Yang, M. (2026) · Vaccines · doi:10.3390/vaccines14100902
Hagstotz, A., Michen, S., Aigner, A., Eyüpoglu, I. Y., & Temme, A. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109134
Yi, S., Seo, E., Hong, K., & Park, P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219457
Rahman, M. A., Kabir, L., Ahmed, N., Barua, A., Hasan, M., & Mahdeen, A. A. (2026) · PLoS ONE · doi:10.1371/journal.pone.0361136
LNP vs LION multivalent in NHPs
Kimura, T. (2026) · ImmPort · doi:10.21430/m32e3x1j9n
mRNA Vaccines and Their Role in Modulating the Immune Response
Abdulqadur, E. A. (2026) · Interdisciplinary Journal of Health Environment and Computation · doi:10.65983/ijhec.2026.01.0004
Ugwu, O. P.-C., Okon, M. B., Ogenyi, F. C., Ugwu, J. N., & Ugwu, C. N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1872123
Metadata
- Authors
- Bloom, K., van den Berg, F., & Arbuthnot, P.
- Affiliations
- South African Medical Research Council (ZA)
- Corresponding author
- Bloom, Kristie
- Venue
- Gene Therapy
- Published
- 2020-10-22
- Volume
- 28
- Issue
- 3-4
- Pages
- 117-129
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- PMC
- PMC7580817
- OpenAlex
- W3093949211
- Cited by
- 487
- References
- 136
- Citations by year
- 2026: 68 · 2025: 107 · 2024: 98 · 2023: 80 · 2022: 71 · 2021: 61 · 2020: 2
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gene Therapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- South African Medical Research Council
- National Research Foundation (118022, 120383)
- Poliomyelitis Research Foundation (18/01)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Keywords
- self-amplifying RNA vaccine, RNA vaccines, infectious disease vaccines, in vitro transcription, SARS-CoV-2, influenza, respiratory syncytial virus, rabies, Ebola, HIV-1, chronic infection
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, RNA, Viral, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
